TORONTO and GATINEAU, QC, May 9,
2023 /PRNewswire/ -- Converge Technology Solutions Corp.
("Converge" or "the Company") (TSX: CTS) (FSE: 0ZB)
(OTCQX: CTSDF) is pleased to provide its financial results for the
three-month period ended March 31,
2023 ("Q1-23"). All figures are in Canadian dollars
unless otherwise stated.
Q1-2023 Financial Highlights:
- Gross sales1 for Q1-23 of $965.3 million compared to $673.9 million in Q1-22; an increase of
$291.4 million or 43%
- Gross Profit of $171.6 million
compared to $109.0 million in Q1-22;
an increase of $62.6 million or
57%
- Organic gross profit growth1 increased to 16.5% from 13.9% in
Q1-22
- Cash flow from operating activities generated $28.8 million, compared to cash used in
operations of $30.2 million in Q1-22,
increasing by $59.0 million
- Adjusted EBITDA1 of $41.2
million, increasing from $29.6
million in Q1-22 by 39%
- Net revenue for Q1-23 of $678.2
million, an increase of 37% over Q1-22
- Product backlog2 grew by $48M from Q4-22 to $527M at the end Q1-23
- Adjusted EPS1 of $0.12 per share
for Q1-23, increasing from $0.10 per
share in Q1-22
- Achieved 103 net new logos in Q1-23
"We are successfully executing against our strategy to
demonstrate continued expansion in profitability and cash
generation, each reaching new highs during Q1 despite current
macro-economic conditions," stated Mr. Shaun Maine, Converge Group CEO. "While the
overall market is expected to remain relatively flat in 2023, with
particular challenges at the large enterprise customer level, we
anticipate that we will gain market share organically, clearly
positioning us as the preferred partner among mid-market customers,
and that we'll see further organic gross profit growth throughout
the remainder of 2023 and beyond."
________________________
|
1 This
is a Non-IFRS measure (including non-IFRS ratio) and not a
recognized, defined or a standardized measure under IFRS. See the
Non-IFRS Financial Measures section of this news release for
definitions, uses and a reconciliation of historical non-IFRS
financial measures to the most directly comparable IFRS financial
measures.
|
2
Product backlog is calculated as purchase orders received from
customers not yet delivered at the end of the fiscal
period.
|
Q1-2023 Business Highlights & Subsequent to Quarter
- Announced the conclusion of the strategic review process and
the dissolution of the Special Committee
- The Board has declared a quarterly dividend of $0.01 per share
- Announced the re-commencement of the Company's normal course
issuer bid ("NCIB")
- Announced the appointment of Avjit Kamboj to Chief Financial
Officer, a finance and technology executive with over 16 years of
experience in capital and international markets
- Converge subsidiary Stone Group earned Global winner Green
World Awards 2023 and Global Silver Winner in Corporate Social
responsibility Category; the Company plans on releasing further ESG
details at upcoming AGM on June 20,
2023
"With the success of our cross-selling strategy, the
Company will be prioritizing organic growth over inorganic
growth moving forward," continued Mr. Maine. "The Company
is also pleased to announce the appointment of Mr. Avjit
Kamboj today as Chief Financial Officer. After leading finance in
the early phase of Converge's growth, Mr. Kamboj will re-join the
executive leadership team of Converge reporting into
myself as Group CEO."
Capital Management Initiatives
In light of the Company's positive net cash flow and on-going
cash generation, the Board of Directors has authorized the
initiation of a quarterly dividend. The Board has declared a
dividend of $0.01 per common share of
the Company in respect of the first quarter of 2023. The dividend
will be paid on or about June 16,
2023 to shareholders of record at the close of business on
June 9, 2023. This dividend is
designated to be an eligible dividend for purposes of Section 89(1)
of the Income Tax Act (Canada).
The Company also intends to resume purchases under the NCIB that
commenced on August 11, 2022. The
NCIB terminates one year after its commencement, or earlier if the
maximum number of common shares under the NCIB have been purchased
or the NCIB is terminated at the option of the Company. As of the
date hereof, 6,464,124 common shares of a maximum of 10,744,818
common shares have been repurchased by the Company under the
NCIB.
Conference Call Details:
Date: Wednesday, May 10th, 2023
Time: 8:00 AM Eastern Time
Participant Webcast Link:
Webcast Link – https://app.webinar.net/Be13rwz0YGB
Participant Dial-in Details with Operator
Assistance:
Confirmation #: 19352249
Toronto: 416-764-8609
North American Toll Free: 888-390-0605
International Toll-Free Numbers:
Germany: 08007240293
Ireland: 1800939111
Spain: 900834776
Switzerland: 0800312635
United Kingdom: 08006522435
You may register and enter your phone number to receive an
instant automated call back
via https://emportal.ink/41om1Vv
Recording Playback:
Webcast Link - https://app.webinar.net/Be13rwz0YGB
Toronto: 416-764-8677
North American Toll Free: 1-888-390-0541
Replay Code: 352249 #
Expiry Date: May 17th, 2023
Please connect at least 15 minutes prior to the conference call
to ensure time for any software download that may be required to
access the webcast. A live audio webcast accompanied by
presentation slides and archive of the conference call and webcast
will be available by visiting the Company's website
at https://convergetp.com/investor-relations/.
About Converge
Converge Technology Solutions Corp. is
a services-led, software-enabled, IT & Cloud Solutions provider
focused on delivering industry-leading solutions. Converge's global
approach delivers advanced analytics, application modernization,
cloud platforms, cybersecurity, digital infrastructure, and digital
workplace offerings to clients across various industries. The
Company supports these solutions with advisory, implementation, and
managed services expertise across all major IT vendors in the
marketplace. This multi-faceted approach enables Converge to
address the unique business and technology requirements for all
clients in the public and private sectors. For more information,
visit convergetp.com.
Summary of Consolidated Statements of Financial
Position
(expressed in thousands of Canadian
dollars)
|
March 31,
2023
|
December 31,
2022
|
Assets
|
|
|
Current
assets
|
|
|
|
Cash
|
$
139,028
|
$
159,890
|
|
Restricted
cash
|
5,105
|
5,230
|
|
Trade and other
receivables
|
784,096
|
781,683
|
|
Inventories
|
157,608
|
158,430
|
|
Prepaid expenses
and other assets
|
25,139
|
23,046
|
|
|
1,110,976
|
1,128,279
|
Long-term
assets
|
|
|
|
Property, equipment,
and right-of-use assets, net
|
79,897
|
88,352
|
|
Intangible assets,
net
|
446,961
|
463,751
|
|
Goodwill
|
566,996
|
563,848
|
|
Other non-current
assets
|
12,061
|
4,646
|
|
|
$
2,216,891
|
$
2,248,876
|
|
|
|
|
Liabilities
|
|
|
Current
liabilities
|
|
|
|
Trade and other
payables
|
$
828,000
|
$
824,924
|
|
Borrowings
|
460,221
|
421,728
|
|
Other financial
liabilities
|
66,741
|
123,932
|
|
Deferred revenue and
other liabilities
|
60,484
|
60,210
|
|
Income taxes
payable
|
5,402
|
7,112
|
|
|
1,420,848
|
1,437,906
|
Long-term
liabilities
|
|
|
|
Other financial
liabilities
|
64,551
|
77,183
|
|
Deferred tax
liability
|
98,513
|
102,977
|
|
|
$
1,583,912
|
$
1,618,066
|
|
|
|
|
Shareholders'
equity
|
|
|
|
Common
shares
|
599,233
|
595,019
|
|
Contributed
surplus
|
8,767
|
7,919
|
|
Exchange
rights
|
-
|
1,705
|
|
Accumulated other
comprehensive income
|
15,881
|
13,708
|
|
Deficit
|
(20,398)
|
(18,441)
|
Total equity
attributable to shareholders of Converge
|
603,483
|
599,910
|
Non-controlling
interest
|
29,496
|
30,900
|
|
|
632,979
|
630,810
|
|
|
2,216,891
|
$
2,248,876
|
Summary of Consolidated Statements of Loss and Comprehensive
Loss
(expressed in thousands of Canadian dollars)
|
|
Three months ended
March 31,
|
|
|
|
2023
|
|
2022
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
|
Product
|
$
|
536,689
|
$
|
397,392
|
|
Service
|
|
141,509
|
|
96,648
|
|
Total
revenue
|
|
678,198
|
|
494,040
|
|
Cost of
sales
|
|
506,610
|
|
384,995
|
|
Gross
profit
|
|
171,588
|
|
109,045
|
|
|
|
|
|
|
|
Selling, general and
administrative expenses
|
|
132,033
|
|
80,412
|
|
Income before the
following
|
|
39,555
|
|
28,633
|
|
Depreciation and
amortization
|
|
25,890
|
|
14,480
|
|
Finance expense,
net
|
|
9,350
|
|
1,818
|
|
Special
charges
|
|
4,284
|
|
5,722
|
|
Share-based
compensation expense
|
|
848
|
|
1,212
|
|
Other
expense
|
|
2,469
|
|
6,403
|
|
Loss before
income taxes
|
|
(3,286)
|
|
(1,002)
|
|
|
|
|
|
|
|
Income tax
expense
|
|
75
|
|
1,406
|
|
|
|
|
|
|
|
Net
loss
|
$
|
(3,361)
|
$
|
(2,408)
|
|
Net loss attributable
to:
|
|
|
|
|
|
Shareholders of
Converge
|
|
(1,957)
|
|
(1,794)
|
|
Non-controlling
interest
|
|
(1,404)
|
|
(614)
|
|
|
$
|
(3,361)
|
$
|
(2,408)
|
|
Other comprehensive
loss
|
|
|
|
|
|
Exchange
(gain) loss on translation of foreign operations
|
|
(2,173)
|
|
6,587
|
|
Comprehensive
loss
|
$
|
(1,188)
|
$
|
(8,995)
|
|
Comprehensive loss
attributable to:
|
|
|
|
|
|
Shareholders of
Converge
|
|
216
|
|
(8,381)
|
|
Non-controlling
interest
|
|
(1,404)
|
|
(614)
|
|
|
$
|
(1,188)
|
$
|
(8,995)
|
|
|
|
|
|
|
|
Adjusted
EBITDA3
|
$
|
41,208
|
$
|
29,649
|
|
Adjusted EBITDA as a
% of Gross Profit3
|
|
24.0 %
|
|
27.2 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
____________________________
|
3 This is a
Non-IFRS measure (including non-IFRS ratio) and not a recognized,
defined or a standardized measure under IFRS. See the Non-IFRS
Financial Measures section of this news release for definitions,
uses and a reconciliation of historical non-IFRS financial measures
to the most directly comparable IFRS financial measures.
|
Summary of Consolidated Statements of Cash
Flows
(expressed in thousands of Canadian
dollars)
|
|
|
|
For the three
months
ended March 31,
|
|
|
|
|
2023
|
|
2022
|
|
|
|
|
|
|
|
Cash flows from
(used in) operating activities
|
|
|
|
|
|
|
Net loss
|
|
|
$
|
(3,361)
|
$
|
(2,408)
|
Adjustments to
reconcile net loss to net cash from operating activities
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
|
27,549
|
|
15,340
|
Unrealized foreign
exchange losses
|
|
|
|
2,463
|
|
6,669
|
Share-based
compensation expense
|
|
|
|
848
|
|
1,212
|
Finance
expense, net
|
|
|
|
9,350
|
|
1,818
|
Income tax
expense
|
|
|
|
75
|
|
1,406
|
|
|
|
|
36,924
|
|
24,037
|
Changes in non-cash
working capital items
|
|
|
|
|
|
|
Trade and other
receivables
|
|
|
|
(2,441)
|
|
(27,773)
|
Inventories
|
|
|
|
1,328
|
|
6,549
|
Prepaid expenses and
other assets
|
|
|
|
(1,426)
|
|
(1,429)
|
Trade and other
payables
|
|
|
|
781
|
|
(29,383)
|
Income taxes
payable
|
|
|
|
(6,925)
|
|
(753)
|
Other financial
liabilities
|
|
|
|
356
|
|
1,917
|
Deferred revenue and
customer deposits
|
|
|
|
166
|
|
(3,385)
|
Cash from (used in)
operating activities
|
|
|
|
28,763
|
|
(30,220)
|
|
|
|
|
|
|
|
Cash flows used in
investing activities
|
|
|
|
|
|
|
Purchase of property
and equipment
|
|
|
|
(5,106)
|
|
(11,356)
|
Proceeds on disposal of
property and equipment
|
|
|
|
68
|
|
177
|
Repayment of contingent
consideration
|
|
|
|
(8,960)
|
|
(10,134)
|
Repayment of deferred
consideration
|
|
|
|
(25,654)
|
|
(1,740)
|
Repayment of NCI
liability
|
|
|
|
(29,994)
|
|
-
|
Business combinations,
net of cash acquired
|
|
|
|
-
|
|
(67,926)
|
Cash used in
investing activities
|
|
|
|
(69,646)
|
|
(90,979)
|
|
|
|
|
|
|
|
Cash flows from
financing activities
|
|
|
|
|
|
|
Transfers from (to)
restricted cash
|
|
|
|
216
|
|
(63,493)
|
Interest
paid
|
|
|
|
(7,877)
|
|
(956)
|
Payments of lease
liabilities
|
|
|
|
(5,135)
|
|
(2,728)
|
Repayment of notes
payable
|
|
|
|
(40)
|
|
(121)
|
Net proceeds from
borrowings
|
|
|
|
34,199
|
|
162,468
|
Cash from financing
activities
|
|
|
|
21,363
|
|
95,170
|
|
|
|
|
|
|
|
Net change in cash
during the period
|
|
|
|
(19,520)
|
|
(26,029)
|
Effect of foreign
exchange on cash
|
|
|
|
(1,342)
|
|
(5,500)
|
Cash, beginning of
period
|
|
|
|
159,890
|
|
248,193
|
Cash, end of
period
|
|
|
$
|
139,028
|
$
|
216,664
|
Non-IFRS Financial Measures
This release refers to certain performance indicators including
Adjusted EBITDA that does not have any standardized meaning
prescribed by IFRS and may not be comparable to similar measures
presented by other companies. Management believes that these
measures are useful to most shareholders, creditors, and other
stakeholders in analyzing the Company's results. These
non-IFRS financial measures should not be considered as an
alternative to the consolidated income (loss) or any other measure
of performance under IFRS.
Adjusted EBITDA
Adjusted EBITDA represents net income or loss adjusted to
exclude amortization, depreciation, interest expense and finance
costs, foreign exchange gains and losses, share-based compensation
expense, income tax expense, and special charges. Special charges
consist primarily of restructuring related expenses for employee
terminations, lease terminations, and restructuring of acquired
companies, as well as certain legal fees or provisions related to
acquired companies. From time to time, it may also include
adjustments in the fair value of contingent consideration, and
other such non-recurring costs related to restructuring, financing,
and acquisitions.
The Company uses Adjusted EBITDA to provide investors with a
supplemental measure of its operating performance and thus
highlight trends in its core business that may not otherwise be
apparent when relying solely on IFRS financial measures. The
Company believes that securities analysts, investors and other
interested parties frequently use non-IFRS measures in the
evaluation of issuers. Management also uses non-IFRS measures to
facilitate operating performance comparisons from period to period,
prepare annual operating budgets and assess the ability to meet
capital expenditure and working capital requirements.
Adjusted EBITDA is not a recognized, defined or standardized
measure under IFRS. The Company's definition of Adjusted EBITDA
will likely differ from that used by other companies and therefore
comparability may be limited. Adjusted EBITDA should not be
considered a substitute for or in isolation from measures prepared
in accordance with IFRS. Investors are encouraged to review
the Company's financial statements and disclosures in their
entirety and are cautioned not to put undue reliance on non-IFRS
measures and view them in conjunction with the most comparable IFRS
financial measures.
The Company has reconciled Adjusted EBITDA to the most
comparable IFRS financial measure as follows:
|
For the three
months
ended March
31,
|
|
2023
|
2022
|
Net loss before
taxes
|
$ (3,286)
|
$
(1,002)
|
Finance
expense
|
9,350
|
1,818
|
Share-based
compensation expense
|
848
|
1,212
|
Depreciation and
amortization
|
25,890
|
14,480
|
Depreciation included
in cost of sales
|
1,659
|
751
|
Foreign exchange
loss
|
2,463
|
6,668
|
Special
charges
|
4,284
|
5,722
|
Adjusted
EBITDA
|
$ 41,208
|
$
29,649
|
Adjusted EBITDA as a % of Gross Profit
The Company believes that Adjusted EBITDA as a % of Gross Profit
is a useful measure of the Company's operating efficiency and
profitability. This is calculated by dividing Adjusted EBITDA by
gross profit.
Adjusted Net Income (Loss) and Adjusted Earnings per Share
("EPS")
Adjusted Net Income (Loss) represents net income (loss) adjusted
to exclude special charges, amortization of acquired intangible
assets, and share-based compensation. The Company believes that
Adjusted Net Income (Loss) is a more useful measure than net income
(loss) as it excludes the impact of one-time, non-cash and/or
non-recurring items that are not reflective of Converge's
underlying business performance. Adjusted EPS is calculated by
dividing Adjusted Net Income (Loss) by the total weighted average
shares outstanding on a basic and diluted basis.
The Company has provided a reconciliation to the most comparable
IFRS financial measure as follows:
|
For the three
months
|
ended March
31,
|
|
2023
|
2022
|
Net loss
|
$
(3,361)
|
$
(2,408)
|
Special
charges
|
4,284
|
5,722
|
Amortization of
acquired intangible assets
|
20,208
|
11,316
|
Foreign exchange
loss
|
2,463
|
6,668
|
Share-based
compensation
|
848
|
1,212
|
Adjusted Net
Income:
|
$
24,442
|
$
22,510
|
Basic
|
0.12
|
0.10
|
Diluted
|
0.12
|
0.10
|
Gross sales and gross sales for organic growth
Gross sales, which is a non-IFRS measurement, reflects the gross
amount billed to customers, adjusted for amounts deferred or
accrued. The Company believes gross sales is a useful alternative
financial metric to net revenue, the IFRS measure, as it better
reflects volume fluctuations as compared to net revenue. Under the
applicable IFRS 15 'principal vs agent' guidance, the principal
records revenue on a gross basis and the agent records commission
on a net basis. In transactions where Converge is acting as an
agent between the customer and the vendor, net revenue is
calculated by reducing gross sales by the cost of sale
amount.
The Company has provided a reconciliation of gross sales to net
revenue, which is the most comparable IFRS financial measure, as
follows:
|
For the three months
ended March 31,
|
|
2023
|
2022
|
Product
|
$
665,310
|
$
453,389
|
Managed
services
|
40,636
|
33,983
|
Third party and
professional services
|
259,312
|
186,557
|
Gross sales
|
$
965,258
|
$
673,929
|
Adjustment for sales
transacted as agent
|
287,060
|
179,889
|
Net revenue
|
$
678,198
|
$
494,040
|
Organic Growth
The Company measures organic growth at the gross sales and gross
profit levels, and includes the contributions under Converge
ownership in the current and comparative period(s). In calculating
organic growth, the Company therefore deducts gross sales and gross
profit generated from companies that were acquired in the current
reporting period.
Gross sales organic growth is calculated by deducting prior
period gross sales, as reported in the Company's public filings,
from current period gross sales for the same portfolio of
companies. Gross sales organic growth percentage is calculated by
dividing organic growth by prior period reported gross sales.
The following table calculates gross sales organic growth for
Q123:
For the three months
ended March 31,
|
Q1
2023
|
Q1 2022
|
Gross sales
|
$
965,258
|
$
673,929
|
Less: gross sales from
companies not owned in comparative period
|
245,630
|
188,685
|
Gross sales of
companies owned in comparative period
|
$
719,628
|
$
485,244
|
Prior period gross
sales
|
673,929
|
408,100
|
Organic Growth -
$
|
$
45,699
|
$
77,144
|
Organic Growth -
%
|
6.8 %
|
18.9 %
|
Gross profit organic growth is calculated by deducting prior
period gross profit, as reported in the Companies public filings,
from current period gross profit for the same portfolio of
companies. Gross profit organic growth percentage is calculated by
dividing organic growth by prior period reported gross profit.
For the three months
ended March 31,
|
Q1
2023
|
Q1 2022
|
Gross profit
|
$
171,588
|
$
109,045
|
Less: gross profit from
companies not owned in comparative period
|
44,597
|
31,808
|
Gross profit of
companies owned in comparative period
|
126,991
|
77,237
|
Prior period gross
profit
|
109,045
|
67,797
|
Organic Growth -
$
|
$
17,946
|
$
9,440
|
Organic Growth -
%
|
16.5 %
|
13.9 %
|
Forward-Looking Information
This press release contains certain "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking statements") within the meaning of
applicable Canadian securities legislation regarding Converge and
its business. Any statement that involves discussions with respect
to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as "expects", or "does not expect",
"is expected" "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts". "estimates", "believes" or
intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could, "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. Forward-looking statements are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking statements. Except as required by law, Converge
assumes no obligation to update the forward-looking statements of
beliefs, opinions, projections, or other factors, should they
change. The reader is cautioned not to place undue reliance
on forward-looking statements.
For a detailed description of the risks and uncertainties facing
the Company and its business and affairs, readers should refer to
the Company's filings statement available on SEDAR under the
Company's profile at www.sedar.com including its most recent Annual
Information Form, its Management Discussion and Analysis and its
Annual and Quarterly Financial Statements.
Converge Technology Solutions Corp., Email:
investors@convergetp.com, Phone: 416-360-1495
View original
content:https://www.prnewswire.co.uk/news-releases/converge-technology-solutions-reports-strong-q1-2023-results-and-declares-quarterly-cash-dividend-301820100.html